Abstract: Systems and apparatuses for blood oxygenation are disclosed. A system includes a first layer defining a plurality of banks of first channels each extending in a first direction. The plurality of banks of first channels are configured to receive blood via a trunk channel. The system includes a second layer defining a bank of second channels extending in a second direction. The bank of second channels are configured to receive oxygen. The first direction is different from the second direction. The system includes a membrane disposed between the first layer and the second layer and configured to cause the oxygen to permeate from the second layer to the first layer to oxygenate the blood.

Abstract: The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE). Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.

Abstract: An apparatus such as a graphics processing unit (GPU) includes a plurality of processing elements configured to concurrently execute a plurality of first waves and accumulators associated with the plurality of processing elements. The accumulators are configured to store accumulated values representative of behavioral characteristics of the plurality of first waves that are concurrently executing on the plurality of processing elements. The apparatus also includes a dispatcher configured to dispatch second waves to the plurality of processing elements based on comparisons of values representative of behavioral characteristics of the second waves and the accumulated values stored in the accumulators. In some cases, the behavioral characteristics of the plurality of first waves comprise at least one of fetch bandwidths, usage of an arithmetic logic unit (ALU), and number of export operations.

Abstract: An apparatus such as a graphics processing unit (GPU) includes a plurality of processing elements configured to concurrently execute a plurality of first waves and accumulators associated with the plurality of processing elements. The accumulators are configured to store accumulated values representative of behavioral characteristics of the plurality of first waves that are concurrently executing on the plurality of processing elements. The apparatus also includes a dispatcher configured to dispatch second waves to the plurality of processing elements based on comparisons of values representative of behavioral characteristics of the second waves and the accumulated values stored in the accumulators. In some cases, the behavioral characteristics of the plurality of first waves comprise at least one of fetch bandwidths, usage of an arithmetic logic unit (ALU), and number of export operations.

Abstract: The present invention provides a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 (“BILAG”) as category A (“BILAG A”) or at least two organ systems categorized as BILAG B comprising periodic administration to the human subject of one subcutaneous injection of 0.25 mg dose of Edratide every week, so as to treat the human subject.

Abstract: Provided is a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 (“BILAG”) as category A (“BILAG A”) or at least two organ systems categorized as BILAG B. The method may include periodic administration to the human subject of one subcutaneous injection of 0.25 mg dose of Edratide every week, so as to treat the human subject.

Abstract: Provided is a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 (“BILAG”) as category A (“BILAG A”) or at least two organ systems categorized as BILAG B. The method may include periodic administration to the human subject of one subcutaneous injection of 0.5 mg dose of Edratide every week, so as to treat the human subject.